Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RVMD | PRESS-RELEASE | neutral | 1/10 | Revolution Medicines, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| GNTA | PRESS-RELEASE | bearish | 7/10 | Genenta Science received a Nasdaq deficiency notice for failing to maintain a minimum $1.00 bid price for 30 consecutive | Oct 21, 2026 |
| BCRX | PRESS-RELEASE | neutral | 1/10 | BioCryst Pharmaceuticals, Inc. announced it will report its Q3 2026 results on November 4. | Oct 21, 2026 |
| CYTK | PRESS-RELEASE | neutral | 1/10 | Cytokinetics, Incorporated announced it will report its Q3 results on November 4, 2026. | Oct 21, 2026 |
| ARQT | PRESS-RELEASE | neutral | 1/10 | Arcutis Biotherapeutics, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| NNVC | 424B5 | neutral | 3/10 | NanoViricides filed Amendment No. 2 to its ATM prospectus supplement, updating the maximum remaining offering amount to | Oct 21, 2026 |
| ABT | 8-K | bullish | 6/10 | Abbott announced its intention to spin off its global Nutrition business (~$8.5B annual sales) into an independent publi | Oct 21, 2026 |
| INMB | 8-K | bullish | 7/10 | INmune Bio filed an 8-K announcing two key Ebstrocel (CORDStrom) milestones: submission of a pre-MAA package to the UK M | Oct 21, 2026 |
| SMMT | PRESS-RELEASE | neutral | 5/10 | Akeso announced that its partner Summit Therapeutics (SMMT) initiated a Phase II/III registrational trial (EA2251) for i | Oct 21, 2026 |
| HYFT | 6-K | neutral | 3/10 | MindWalk published a white paper showing its LensAI immunogenicity screening ran 890,634 antibody sequences in under 5 h | Oct 21, 2026 |
| IMNN | 8-K | neutral | 4/10 | Imunon entered into an asset purchase agreement to sell its ThermoDox program to VoxelDox Therapeutics. The deal is cont | Oct 21, 2026 |
| VYGR | 8-K | neutral | 3/10 | Voyager Therapeutics promoted Robin Swartz from COO/CBO to President, effective October 20, 2026, with a plan for her to | Oct 21, 2026 |
| ABT | 8-K | bearish | 6/10 | Abbott reported Q3 2026 adjusted diluted EPS of $1.42, missing consensus of $1.64 by 13.4%, and revenue of $13.013B vs $ | Oct 21, 2026 |
| ABT | PRESS-RELEASE | neutral | 4/10 | Abbott reported Q3 2026 EPS of $1.42, a 0.4% beat versus the consensus estimate of $1.41, on revenue of $12.99B (in line | Oct 21, 2026 |
| ROIV | 8-K | bullish | 7/10 | Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious uveitis (NIU). | Oct 21, 2026 |
| GNPX | 8-K | neutral | 2/10 | Genprex issued a press release highlighting peer-reviewed mouse research on the TUSC2 tumor suppressor gene's role in br | Oct 21, 2026 |
| VVOS | 8-K | neutral | 4/10 | Vivos Therapeutics received a letter from Nasdaq on October 20, 2026 confirming compliance with the minimum stockholders | Oct 21, 2026 |
| MSLE | 6-K | neutral | 2/10 | Satellos Bioscience announced management participation in two upcoming investor conferences (Guggenheim Healthcare Innov | Oct 21, 2026 |
| RDHL | 6-K | neutral | 3/10 | RedHill Biopharma regained ex-North America rights to RHB-102 after terminating its license agreement with Hyloris Pharm | Oct 21, 2026 |
| TLSA | 6-K | neutral | 2/10 | Tiziana Life Sciences announced that management will attend the joint ACTRIMS-ECTRIMS meeting (MSToronto2026) in Toronto | Oct 21, 2026 |
| PBM | 6-K | mixed | 5/10 | Psyence Biomedical completed its backstop investment of $2.6 million in PsyLabs after both ibogaine milestones were met: | Oct 21, 2026 |
| RDY | 6-K | bullish | 5/10 | Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for first-line | Oct 21, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B, a first-in-class antisense oligonucleotide | Oct 21, 2026 |
| IPHA | 6-K | neutral | 2/10 | Innate Pharma announced management participation in the Stifel Healthcare Conference (Nov 10-12, 2026) and Jefferies Glo | Oct 21, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED closed the exclusive license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted the | Oct 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on October 21, 2026, solely to furnish a Notice of Annual General Meeting and pro | Oct 21, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a 6-K disclosing changes to CEO Dr. David Stamler's remuneration package, effective October | Oct 21, 2026 |
| GTBP | EFFECT | bearish | 6/10 | GT Biopharma's S-1 registration (File No. 333-299408) became effective on October 20, 2026, covering up to 9,723,057 sha | Oct 21, 2026 |
| DRMA | EFFECT | bearish | 6/10 | Dermata Therapeutics' S-3 shelf registration (File No. 333-299391) was declared effective on October 20, 2026, enabling | Oct 21, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two insiders at Oruka Therapeutics sold a total of $534K in open-market sales within a week. The CMO exercised and sold | Oct 20, 2026 |